维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="Pietzner"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	Bevacizumab in heavily pre-treated and Platinum resistant ovarian Cancer:a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO)Ovarian Cancer Study Group显示文摘	Pietzner K Richter R Chekerov R		0，，08：	1
2	Stakeholder Acceptance of Carbon Capture and Storage in Germany 显示文摘	Fischedick M Pietzner K Supersberger N	2009	Energy Procedia2009，1，1：	1
3	Theincidence of intraoperative awareness in cardiac surgery fast-track treatment 显示文摘	GROESDONK H V PIETZNER J BORGER M A	2010	J Cardiothorac Vase Anesth2010，24，5：	1
4	Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO)Ovarian Cancer Study Group 显示文摘	Pietzner K Richter R Chekerov R	2011	Anticancer Res2011，31，11：	1
5	Clinical experience of young patients with small cell ovarian carcinoma of the hypercalce- raic type (OSCCHT) 显示文摘	Woopen H Sehouli J Pietzner K	2012	Euro J of Obst & Gyne and Repr Biol2012，165，2：	1
6	The incidence of intraopera- rive awareness in cardiac surgery fast-track treatment 显示文摘	Groesdonk HV Pietzner J Borger MA	2010	Cardiothorac Vase Anesth2010，24，5：	1
7	Optimizing the clinical management of gynecological and breast cancer via online tumor conferences显示文摘	Schroeder JK Kuemmel S Pietzner K	2011	Anticancer Res2011，31，8：	1
8	Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer : results of a German multiceuter study显示文摘	Sehouli J Pietzner K Harter P	2010	Ann Oncol2010，21，11：	1
9	Prognostic role of platinum sensitivity in patients with brain metastases from ovariart cancer: results of a German multicenter study显示文摘	Sehouli J Pietzner K Harter P	2010	Ann Oncol2010，21，11：	1
10	Brain metastases from epithelial ovarian cancer: overview and optimal management 显示文摘	Pietzner K Oskay-Oezeelik GE Khalfaoui K	2009	Anticancer Res2009，29，7：	1
11	Two-year results after lumbar microdiscectomy with and without prophylaxis of a peridural fibrosis using Adcon-L显示文摘	Dirk Ganzer Katrin Giese Lutz V?lker Uwe Pietzner Niels Follak Harry Merk	2003	Archives of Orthopaedic and Trauma Surgery2003，，1：	1
12	The incidenceof intraoperative awareness in cardiac surgery fast-track treatment 显示文摘	Groesdonk H V Pietzner J Borger M A	2010	J Cardiothorac Vasc Anesth2010，24，5：	1
13	Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncolo- gy(NOGGO) ovarian cancer study group 显示文摘	Pietzner K Richter R Chekerov R	2011	Anticancer Res2011，31，8：	1
14	Clinical experience of young patients with small cell ovarian carcinoma of the hypercalcemic type(OSCCHT)显示文摘	Woopen H Sehouli J Pietzner K	2012	Eur J Obstet Gynecol Reprod Biol2012，165，2：	1
15	Brain metastases from epithelial ovarian cancer: overview and optimal management 显示文摘	Pietzner K Oskay-Oezeelik GE Khalfaoui K	2009	Anticaneer Res2009，29，7：	1
16	Bevacizumab in heavily pre-treated and Platinum resistant ovarian Cancer:a retro- spective study of the North-Eastern Ger- man Society of Gynaecologic Oncology (NOGGO)Ovarian Cancer Study Group显示文摘	Pietzner K Richter R Chekerov R eta\|	2011	Anticancer Res2011，31，8：	1
17	Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer:results of the randomised phase IIIb CASIMAS study显示文摘	Sehouli J Pietzner K Wimberger P	2014	Med Oncol2014，31，8：	1
18	Liposarcoma of the breast arising in a malignant phyllodes tumor:A case report and review of the literature显示文摘Liposarcoma of the breast is a very rare malignant tumor. It can clinically manifest as a palpable breast mass and mimic primary breast cancer. We report an unusual case of a 51-year-old female who presented with an asymptomatic right breast mass, which was histologically diagnosed as well differentiated liposarcoma arisen within malignant phyllodes tumor. The patient underwent breast conserving surgery, received no adjuvant treatment and is disease-free after 2 years. Radiological and histopathological features are presented and described in detail. Data from the literature are presented and therapy recommendations discussed.	Malgorzata Banys-Paluchowski Eike Burandt Alexander Quaas Waldemar Wilczak Stefan Geist Guido Sauter Natalia Krawczyk Klaus Pietzner Peter Paluchowski	2015	World Journal of Clinical Oncology2015，6，5：	1
19	Pseudo-or real progression? An ovarian cancer patient under nivolumab:A case report显示文摘BACKGROUND Checkpoint-Inhibition has revolutionized the treatment for several entities such as melanoma and renal cell carcinoma.The first encouraging experience in ovarian cancer was reported for nivolumab,a fully humanized anti-programmed death-1 antibody.Pseudoprogression is a new phenomenon associated with these novel immuno-oncologic agents.It can be explained by infiltrating leucocytes and edema that result in a temporary increase in tumor size and delayed subsequent shrinkage due to tumor cell destruction.CASE SUMMARY We report on a 47-year old patient with platinum-resistant ovarian cancer that was treated off-label with nivolumab 3mg/kg iv d1q14d.She first experienced classic pseudoprogression with inguinal lymph node swelling after cycle two and subsequent shrinkage.After 6 cycles she presented with rectal bleeding and progressive disease was diagnosed due to new tumor infiltration into the rectum.CONCLUSION Clinicians should be aware of pseudoprogression,its underlying mechanisms and strategies to discriminate pseudo-from real progression in ovarian cancer.	Mona Passler Eliane T Taube Jalid Sehouli Klaus Pietzner	2019	World Journal of Clinical Oncology2019，10，7：	0
20	Mapping the proteo-genomic convergence of human diseases显示文摘Characterization of the genetic regulation of proteins is essential for understanding disease etiology and developing therapies.We identified 10,674 genetic associations for 3892 plasma proteins to create a cis-anchored gene-protein-disease map of 1859 connections that highlights strong cross-disease biological convergence.This proteo-genomic map provides a framework to connect etiologically related diseases,to provide biological context for new or emerging disorders,and to integrate different biological domains to establish mechanisms for known gene-disease links.Our results identify proteo-genomic connections within and between diseases and establish the value of cis-protein variants for annotation of likely causal disease genes at loci identified in genome-wide association studies,thereby addressing a major barrier to experimental validation and clinical translation of genetic discoveries.	Maik Pietzner	2023	四川生理科学杂志2023，45，8：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示